Product Program year 2025 Source: CMS Open Payments

Ryzneuta

Drug Oncology

Open in the dashboard

General payments

$45,467

170 payments

Research payments

$0

0 payments

Through program year 2025, $45,467 in general payments and $0 in research payments were reported against Ryzneuta (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $1,035 43
2024 General $44,433 127

Breakdown

Who paid General payments · program years 2024–2025
  1. Acrotech Biopharma LLC $45,467 170 payments
Top recipients General payments · program year 2025
  1. Ellsworth Grant Hematology & Oncology · Los Angeles, CA $63 6% · 1 payment
  2. Ahmad Fora Medical Oncology · Olympia, WA $46 4% · 1 payment
  3. Cheyenne Hardy Physician Assistant · Olympia, WA $46 4% · 1 payment
  4. Erlinda Gordon Pediatric Hematology-Oncology · Monterey, CA $35 3% · 1 payment
  5. Neal Chawla Hematology & Oncology · Santa Monica, CA $35 3% · 1 payment

The top 5 of 43 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $457 46% · 18 practitioners
  2. Physician Assistant $218 22% · 8 practitioners
  3. Nurse Practitioner $80 8% · 5 practitioners
  4. Medical Oncology Internal Medicine $46 5% · 1 practitioner
  5. Internal Medicine $38 4% · 2 practitioners

The top 5 of 11 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $346 33% · 12 recipients
  2. New Jersey $211 20% · 11 recipients
  3. Alaska $145 14% · 5 recipients
  4. Washington $126 12% · 3 recipients
  5. Texas $68 7% · 4 recipients

The top 5 of 10 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

170 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record